-- 摩根士丹利周三在一份报告中指出，在即将上任的首席执行官西尔维奥·那不勒斯（Silvio Napoli）有时间评估公司业务及其前景之前，Lucid (LCID) 的股价预计将持续承压。 报告显示，该公司在经历了“充满挑战”的第一季度后，暂停了全年的交付量和资本支出指引。管理层报告称，经调整后的息税折旧摊销前利润（EBITDA）亏损达7.81亿美元。 摩根士丹利表示，预计亏损将持续高企，直至计划于2027年推出的中型车。为了弥补亏损，Lucid已宣布从沙特阿拉伯公共投资基金、优步（UBER）以及注册公开发行等渠道筹集总计10.5亿美元的资金。 摩根士丹利将2026年EBITDA预期下调了15%，原因是近期业绩不佳导致毛利率下降，以及由于近期裁员支出导致运营费用增加。该公司还表示，预计全年交付量仍为26,000辆，高于市场普遍预期的25,000辆。 摩根士丹利将该股的目标股价从10美元下调至5美元，同时维持“减持”评级。
Price: $5.90, Change: $-0.35, Percent Change: -5.65%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%